[
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "AKT Inhibitors",
    "phenotype": "Erythema multiforme-like rash",
    "cut_id": "CUT006",
    "incidence": "Not specified",
    "tti": "Not specified",
    "management_prevention": "Management: Topical steroids, systemic steroids for severe cases.",
    "drug_examples": [
      "Capivasertib"
    ],
    "drug_examples_raw": "Capivasertib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "AKT Inhibitors",
    "phenotype": "Maculopapular Rash",
    "cut_id": "CUT027",
    "incidence": "~56%",
    "tti": "1-2 weeks",
    "management_prevention": "Management: Topical steroids, antihistamines. Similar to PI3K inhibitor rash management.",
    "drug_examples": [
      "Capivasertib"
    ],
    "drug_examples_raw": "Capivasertib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "AKT Inhibitors",
    "phenotype": "Stomatitis / mIAS",
    "cut_id": "CUT040",
    "incidence": "Lower frequency than mTOR inhibitors",
    "tti": "Not specified",
    "management_prevention": "Prevention: Alcohol-free Dexamethasone mouthwash (0.5 mg/5 mL) swish and spit 4 times daily. Management: Grade 1: Non-alcoholic mouthwash, salt water. Grade 2: Topical steroids (Triamcinolone), topical anesthetics. Hold drug. Grade 3: Interrupt drug until Grade ≤1, then restart at reduced dose. Avoid alcohol/hydrogen peroxide mouthwashes.",
    "drug_examples": [
      "Capivasertib",
      "Ipatasertib"
    ],
    "drug_examples_raw": "Capivasertib, Ipatasertib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Acneiform Rash (Acneiform eruption)",
    "cut_id": "CUT042",
    "incidence": "~68% less common than maculo-papular rash",
    "tti": "Within 2 weeks (Mean 1.6 weeks)",
    "management_prevention": "Prevention: Hypoallergenic moisturizers, tepid showers. Management: Grade 1: Moisturizers, topical steroids, topical antibiotics (Clindamycin). Grade 2: Oral antihistamines, mid-potency topical steroids. Grade 3: Interruption or dose reduction, systemic steroids.",
    "drug_examples": [
      "Vemurafenib",
      "Dabrafenib",
      "Encorafenib"
    ],
    "drug_examples_raw": "Vemurafenib, Dabrafenib, Encorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Alopecia",
    "cut_id": "CUT001",
    "incidence": "8-36%",
    "tti": "Early onset but not specified",
    "management_prevention": "Usually nonscarring and reversible. Management: Wigs (Grade 1), Minoxidil (may help shorten duration), topical steroids (non-scarring).",
    "drug_examples": [
      "Vemurafenib",
      "Dabrafenib",
      "Encorafenib"
    ],
    "drug_examples_raw": "Vemurafenib, Dabrafenib, Encorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Hand-Foot Syndrome (HFSR, Hyperkeratotic plaques)",
    "cut_id": "CUT039",
    "incidence": "34% (Sorafenib) High prevalence of hyperkeratosis in BRAFi",
    "tti": "BRAFi: 8-36 weeks (Peak 6-12 weeks); Sorafenib: 4-8 weeks",
    "management_prevention": "Prevention: Comfortable shoes, thick cotton socks, remove calluses beforehand. Management: Grade 1: Keratolytics (Urea 10-40%, Salicylic acid) and moisturizers. Grade 2+: Potent topical steroids (Clobetasol), topical anesthetics (Lidocaine), analgesics (NSAIDs, GABA agonists). Severe: Interrupt drug.",
    "drug_examples": [
      "Sorafenib (High frequency)",
      "Vemurafenib",
      "Dabrafenib",
      "Encorafenib"
    ],
    "drug_examples_raw": "Sorafenib (High frequency), Vemurafenib, Dabrafenib, Encorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Keratinizing Skin Tumors (cuSCC, Keratoacanthoma, Papilloma)",
    "cut_id": "CUT045",
    "incidence": "29-30% (BRAFi monotherapy)",
    "tti": "Vemurafenib: Median 8 weeks; Sorafenib: 1-9 months",
    "management_prevention": "Prevention: Regular full-body skin exam (every 4-8 weeks), Strict sun protection. Management: Surgical excision (standard) or shave removal. No need to stop/reduce drug. Local/Systemic therapy (5-FU, Imiquimod, Acitretin) for multiple lesions.",
    "drug_examples": [
      "Vemurafenib",
      "Dabrafenib",
      "Encorafenib",
      "Sorafenib"
    ],
    "drug_examples_raw": "Vemurafenib, Dabrafenib, Encorafenib, Sorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Panniculitis",
    "cut_id": "CUT049",
    "incidence": "13%(Vemurafenib), 3%(Dabrafenib)",
    "tti": "Not specified",
    "management_prevention": "Management: Rest, leg elevation, NSAIDs, systemic steroids. Usually resolves without stopping the drug.",
    "drug_examples": [
      "Vemurafenib",
      "Dabrafenib",
      "Encorafenib"
    ],
    "drug_examples_raw": "Vemurafenib, Dabrafenib, Encorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Photosensitivity",
    "cut_id": "CUT023",
    "incidence": "30-52% (Vemurafenib) very low for Dabrafenib",
    "tti": "Within 24 hours of sunlight exposure",
    "management_prevention": "Prevention: Strict sun protection (UVA block, SPF 30+, PA+++), protective clothing (long sleeves, hats). Caution with window glass. Management: Topical steroids, cold compress, NSAIDs. Grade 2+: Consider dose reduction or interruption.",
    "drug_examples": [
      "Vemurafenib (High frequency)",
      "Dabrafenib (Very low frequency)"
    ],
    "drug_examples_raw": "Vemurafenib (High frequency), Dabrafenib (Very low frequency)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "BRAF Inhibitors",
    "phenotype": "Rash maculo-papular (Maculopapular rash)",
    "cut_id": "CUT027",
    "incidence": "~68% (Vemurafenib)",
    "tti": "Within 2 weeks (Mean 1.6 weeks)",
    "management_prevention": "Prevention: Hypoallergenic moisturizers, tepid showers. Management: Grade 1: Moisturizers, topical steroids (Hydrocortisone, Triamcinolone), topical antibiotics. Grade 2: Oral antihistamines, mid-potency topical steroids. Grade 3: Interruption or dose reduction, systemic steroids (Prednisolone 0.5mg/kg).",
    "drug_examples": [
      "Vemurafenib (Most common)",
      "Dabrafenib",
      "Encorafenib"
    ],
    "drug_examples_raw": "Vemurafenib (Most common), Dabrafenib, Encorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Acneiform Rash (Acneiform/papulopustular rash)",
    "cut_id": "CUT042",
    "incidence": "43-85%",
    "tti": "Onset: 1-2 weeks. Peak: 3-4 weeks",
    "management_prevention": "Prevention: Pre-emptive oral tetracyclines (Minocycline/Doxycycline 100mg), topical steroids (Hydrocortisone 1%), moisturizers, sun protection. Management: Grade 1: Topical steroids (Hydrocortisone, Alclometasone), topical antibiotics (Clindamycin, Metronidazole). Grade 2: Oral antibiotics (Doxycycline/Minocycline 100mg). Grade 3: Hold/reduce dose; Oral antibiotics + short-term oral corticosteroids (Prednisolone 0.5 mg/kg); Low-dose Isotretinoin for refractory cases.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Alopecia (Mild, Androgenetic pattern)",
    "cut_id": "CUT001",
    "incidence": "Rare/Mild",
    "tti": "2-3 months",
    "management_prevention": "Management: Wigs (Grade 1), Topical Minoxidil (may help shorten duration), topical steroids (non-scarring).",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Dry skin (Xerosis) and Fissures",
    "cut_id": "CUT004",
    "incidence": "~35%",
    "tti": "1-2 months (30-60 days)",
    "management_prevention": "Prevention: Avoid irritants (alcohol, perfume), use tepid water, moisturizers BID. Management: Xerosis: Moisturizers with Urea/Lactic acid/Salicylic acid; Topical steroids (Grade 3). Fissures: Liquid bandage (Cyanoacrylate), hydrocolloid dressing, Zinc oxide, topical antibiotics, Lidocaine.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Hair color changes (Poliosis)",
    "cut_id": "CUT008",
    "incidence": "Not specified",
    "tti": "2-3 months",
    "management_prevention": "Management: Cosmetic camouflage (Wigs, etc.) if associated with hair loss.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Hair texture abnormal (Brittle, kinky, curly hair, slower growth)",
    "cut_id": "CUT009",
    "incidence": "Not specified",
    "tti": "2-3 months",
    "management_prevention": "Management: Wigs (if alopecia occurs), topical Minoxidil or steroids for associated hair loss.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Hirsutism (Unwanted hair growth in women)",
    "cut_id": "CUT010",
    "incidence": "Not specified",
    "tti": "2-3 months",
    "management_prevention": "Management: Depilatory creams, laser hair removal, Eflornithine cream.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Hypertrichosis (Trichomegaly of eyelashes)",
    "cut_id": "CUT013",
    "incidence": "~30% (Trichomegaly)",
    "tti": "2-3 months",
    "management_prevention": "Management: Trichomegaly: Regular trimming to prevent corneal damage/keratitis. Ophthalmology consultation if severe.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Oral Mucositis / Stomatitis",
    "cut_id": "CUT040",
    "incidence": "Not specified",
    "tti": "Not specified",
    "management_prevention": "Management: Oral hygiene (soft toothbrush), avoid irritants. Topical steroids (Triamcinolone), Lidocaine, antibiotic gargle.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Periungual / Nail Fold Toxicity (Paronychia, Pyogenic granuloma)",
    "cut_id": "CUT041",
    "incidence": "17.2-50%",
    "tti": "4-8 weeks (or 2-6 months)",
    "management_prevention": "Prevention: Avoid trauma/cutting nails too short, vinegar or chloramine soaks, prophylactic Doxycycline. Management: Grade 1: Topical potent steroids (Clobetasol) or antibiotics (Mupirocin), antiseptic soaks. Grade 2: Silver nitrate cauterization, oral antibiotics, topical beta-blockers (Timolol/Betaxolol). Grade 3: Partial nail avulsion.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab",
      "Necitumumab",
      "Nimotuzumab",
      "Matuzumab",
      "Zalutumumab TKIs: Gefitinib",
      "Erlotinib",
      "Lapatinib",
      "Afatinib",
      "Dacomitinib",
      "Neratinib",
      "Osimertinib",
      "Icotinib",
      "Mobocertinib",
      "Poziotinib"
    ],
    "drug_examples_raw": "mAbs: Cetuximab, Panitumumab, Necitumumab, Nimotuzumab, Matuzumab, Zalutumumab TKIs: Gefitinib, Erlotinib, Lapatinib, Afatinib, Dacomitinib, Neratinib, Osimertinib, Icotinib, Mobocertinib, Poziotinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "EGFR Inhibitors",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": "18.2% (Cetuximab) - 54.9% (Panitumumab)",
    "tti": "1-2 months (associated with xerosis)",
    "management_prevention": "Prevention: Moisturizing, tepid water. Management: Grade 1: Topical steroids, Menthol, Pramoxine. Grade 2: Oral antihistamines (non-sedating/sedating) + topical steroids. Grade 3: GABA agonists (Gabapentin/Pregabalin), Aprepitant (NK-1 antagonist), short-term oral Prednisone.",
    "drug_examples": [
      "Cetuximab",
      "Panitumumab (and others)"
    ],
    "drug_examples_raw": "Cetuximab, Panitumumab (and others)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Acneiform/papulopustular eruption (No comedones)",
    "cut_id": "CUT042",
    "incidence": "74-93%",
    "tti": "1-3 weeks (Rapid onset)",
    "management_prevention": "Prevention: Hypoallergenic cleansers/moisturizers, sun protection. Consider pre-emptive oral antibiotics (Minocycline or Doxycycline). Management: Grade 1-2: Topical steroids (Class 3-4), topical antibiotics (Clindamycin), oral antihistamines for pruritus. Grade 3: Interrupt/reduce dose, oral antibiotics (Tetracycline), short-term systemic steroids (Prednisone 0.5-1 mg/kg). Culture to rule out infection.",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Alopecia",
    "cut_id": "CUT001",
    "incidence": "8-33%",
    "tti": "After 3-4 months",
    "management_prevention": "Management: Wigs (Grade 1), Topical Minoxidil (may help shorten duration), topical steroids (non-scarring).",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Dry skin (Xerosis)",
    "cut_id": "CUT004",
    "incidence": "30-90% (Combined with eczema)",
    "tti": "Within 6 months (Can be slow or persistent)",
    "management_prevention": "Management: Apply emollients (moisturizers) BID or more. Urea-containing creams may help.",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Eczematous dermatitis",
    "cut_id": "CUT005",
    "incidence": "30-90% (Combined with xerosis)",
    "tti": "Within 6 months",
    "management_prevention": "Management: Topical steroids for inflammatory lesions. Antihistamines or GABA agonists for severe pruritus.",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Edema (Peripheral edema, Periorbital/Facial edema)",
    "cut_id": "CUT038",
    "incidence": "20-50% (Peripheral)",
    "tti": "Weeks to months",
    "management_prevention": "Management: Compression therapy, leg elevation. Diuretics or dose adjustment for severe cases.",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Hair texture abnormal",
    "cut_id": "CUT009",
    "incidence": "4-50%",
    "tti": "After 3-4 months",
    "management_prevention": "Management: Regular trimming",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Oral Mucositis / Stomatitis",
    "cut_id": "CUT040",
    "incidence": "8-30%",
    "tti": "After 3-4 months",
    "management_prevention": "Management: Oral hygiene maintenance. Topical steroid gargle/application. Local anesthetics for pain.",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Paronychia (Periungual inflammation)",
    "cut_id": "CUT041",
    "incidence": "30-50%",
    "tti": "Around 12 months (or 48 weeks)",
    "management_prevention": "Prevention: Comfortable shoes, do not cut nails too short, avoid cuticle removal. Vinegar or diluted bleach soaks. Management: Mild: Potent topical steroids (Clobetasol), topical antibiotics (Mupirocin), antiseptic/warm saline soaks. Moderate+: Oral antibiotics (Doxycycline). Silver nitrate or surgery for granuloma.",
    "drug_examples": [
      "Selumetinib (Frequent)",
      "Trametinib (Frequent)",
      "Cobimetinib",
      "Binimetinib"
    ],
    "drug_examples_raw": "Selumetinib (Frequent), Trametinib (Frequent), Cobimetinib, Binimetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "MEK Inhibitors",
    "phenotype": "Skin hypopigmentation (Pigmentary dilution)",
    "cut_id": "CUT031",
    "incidence": "9-12%",
    "tti": "After 1-2 months",
    "management_prevention": "Prevention: Photoprotection. Management: Topcial steroid",
    "drug_examples": [
      "Trametinib",
      "Cobimetinib",
      "Binimetinib",
      "Selumetinib"
    ],
    "drug_examples_raw": "Trametinib, Cobimetinib, Binimetinib, Selumetinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Acneiform Rash",
    "cut_id": "CUT042",
    "incidence": "25-47% (Combined rash types)",
    "tti": "1-2 weeks",
    "management_prevention": "Management: Topical steroids, antibiotics.",
    "drug_examples": [
      "Everolimus",
      "Temsirolimus",
      "Sirolimus",
      "Ridaforolimus"
    ],
    "drug_examples_raw": "Everolimus, Temsirolimus, Sirolimus, Ridaforolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Dry skin (Xerosis)",
    "cut_id": "CUT004",
    "incidence": "Common",
    "tti": "Not specified",
    "management_prevention": "Prevention: Start emollients at the beginning of therapy. Management: Apply thick moisturizers frequently. Use creams containing Urea 10-40% or Ammonium lactate 12% for severe cases.",
    "drug_examples": [
      "Temsirolimus",
      "Everolimus"
    ],
    "drug_examples_raw": "Temsirolimus, Everolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Eczematous dermatitis (Eczematoid rash)",
    "cut_id": "CUT005",
    "incidence": "25-47% (Combined rash types)",
    "tti": "1-2 weeks",
    "management_prevention": "Management: Topical steroids, moisturizers.",
    "drug_examples": [
      "Everolimus",
      "Temsirolimus",
      "Sirolimus",
      "Ridaforolimus"
    ],
    "drug_examples_raw": "Everolimus, Temsirolimus, Sirolimus, Ridaforolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Hand-Foot Skin Reaction (HFSR)",
    "cut_id": "CUT039",
    "incidence": "1-10% (Rare)",
    "tti": "Not specified",
    "management_prevention": "Management: Moisturizers, keratolytics, topical steroids.",
    "drug_examples": [
      "Everolimus"
    ],
    "drug_examples_raw": "Everolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Nail changes (Brittle nails)",
    "cut_id": "CUT016",
    "incidence": "Not specified",
    "tti": "Few weeks - few months",
    "management_prevention": "Management: Protective measures, moisturizers.",
    "drug_examples": [
      "Not specified (Class effect)"
    ],
    "drug_examples_raw": "Not specified (Class effect)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Nail loss (Onycholysis)",
    "cut_id": "CUT018",
    "incidence": "Not specified",
    "tti": "Few weeks - few months",
    "management_prevention": "Management: Keep nails short, avoid trauma.",
    "drug_examples": [
      "Not specified (Class effect)"
    ],
    "drug_examples_raw": "Not specified (Class effect)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Paronychia (Periungual inflammation)",
    "cut_id": "CUT041",
    "incidence": "Not specified",
    "tti": "Few weeks - few months",
    "management_prevention": "Management: Topical antibiotic ointment, topical steroids, vinegar soaks. Treat similarly to EGFR inhibitor toxicity.",
    "drug_examples": [
      "Not specified (Class effect)"
    ],
    "drug_examples_raw": "Not specified (Class effect)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": "0.4",
    "tti": "Not specified",
    "management_prevention": "Management: Moisturizers, Oral antihistamines, Topical steroids.",
    "drug_examples": [
      "Temsirolimus"
    ],
    "drug_examples_raw": "Temsirolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Pyogenic granuloma (Granuloma-like lesions)",
    "cut_id": "CUT041",
    "incidence": "Not specified",
    "tti": "Few weeks - few months",
    "management_prevention": "Management: Silver nitrate, surgical intervention if necessary.",
    "drug_examples": [
      "Not specified (Class effect)"
    ],
    "drug_examples_raw": "Not specified (Class effect)"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Rash maculo-papular (Morbilliform rash)",
    "cut_id": "CUT027",
    "incidence": "25-47% (Combined rash types)",
    "tti": "1-2 weeks",
    "management_prevention": "Management: Topical steroids, antihistamines.",
    "drug_examples": [
      "Everolimus",
      "Temsirolimus",
      "Sirolimus",
      "Ridaforolimus"
    ],
    "drug_examples_raw": "Everolimus, Temsirolimus, Sirolimus, Ridaforolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "mTOR Inhibitors",
    "phenotype": "Stomatitis / mIAS (Aphthous-like ulcers)",
    "cut_id": "CUT040",
    "incidence": "30-44% (Monotherapy)",
    "tti": "Within 8 weeks",
    "management_prevention": "Prevention: Alcohol-free Dexamethasone mouthwash (0.5 mg/5 mL) swish and spit 4 times daily. Management: Grade 1: Non-alcoholic mouthwash, salt water. Grade 2: Topical steroids (Triamcinolone), topical anesthetics. Hold drug. Grade 3: Interrupt drug until Grade ≤1, then restart at reduced dose. Avoid alcohol/hydrogen peroxide mouthwashes.",
    "drug_examples": [
      "Everolimus",
      "Temsirolimus",
      "Sirolimus (Rapamycin)",
      "Ridaforolimus"
    ],
    "drug_examples_raw": "Everolimus, Temsirolimus, Sirolimus (Rapamycin), Ridaforolimus"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Acneiform Rash",
    "cut_id": "CUT042",
    "incidence": "Rare",
    "tti": "1-8 weeks",
    "management_prevention": "Management: Similar to general rash management (Topical steroids, etc.).",
    "drug_examples": [
      "Sorafenib",
      "Sunitinib",
      "Pazopanib",
      "Regorafenib",
      "Cabozantinib",
      "Vandetanib",
      "Lenvatinib",
      "Axitinib"
    ],
    "drug_examples_raw": "Sorafenib, Sunitinib, Pazopanib, Regorafenib, Cabozantinib, Vandetanib, Lenvatinib, Axitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Alopecia",
    "cut_id": "CUT001",
    "incidence": "Sorafenib (44%), Sunitinib (5-21%), Pazopanib (8-10%)",
    "tti": "5-6 weeks",
    "management_prevention": "Management: Wigs (Grade 1), Topical Minoxidil (may help shorten duration), topical steroids (non-scarring).",
    "drug_examples": [
      "Sorafenib",
      "Sunitinib",
      "Pazopanib"
    ],
    "drug_examples_raw": "Sorafenib, Sunitinib, Pazopanib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Hair color changes (Depigmentation, Yellowing)",
    "cut_id": "CUT008",
    "incidence": ">10%",
    "tti": "5-6 weeks",
    "management_prevention": "Management: No treatment required. Reversible.",
    "drug_examples": [
      "Sunitinib",
      "Pazopanib"
    ],
    "drug_examples_raw": "Sunitinib, Pazopanib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Hand-Foot Skin Reaction (HFSR) (Hyperkeratotic plaques, callus, blistering)",
    "cut_id": "CUT039",
    "incidence": "Sorafenib (10-60%), Sunitinib (10-50%)",
    "tti": "Within 26 weeks (mainly 24 weeks)",
    "management_prevention": "Prevention: Remove calluses before treatment. Wear comfortable shoes with insoles and thick cotton socks. Prophylactic Urea 10% cream. Management: Grade 1: Moisturizers, Keratolytics (Urea 20-40%, Salicylic acid 6%), Cushioning. Grade 2: Potent topical steroids (Clobetasol 0.05%), Topical anesthetics (Lidocaine 2-5%). Grade 3: Interrupt drug (min. 7 days). Oral analgesics (NSAIDs, GABA agonists, Opioids).",
    "drug_examples": [
      "Sorafenib",
      "Sunitinib",
      "Regorafenib",
      "Cabozantinib",
      "Pazopanib",
      "Vandetanib",
      "Lenvatinib",
      "Axitinib"
    ],
    "drug_examples_raw": "Sorafenib, Sunitinib, Regorafenib, Cabozantinib, Pazopanib, Vandetanib, Lenvatinib, Axitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Keratinizing Skin Tumors (cuSCC, Keratoacanthoma)",
    "cut_id": "CUT045",
    "incidence": "Rare(0.1-1%)",
    "tti": "After 2-36 months",
    "management_prevention": "Management: Surgical excision or cryotherapy. Drug interruption is not required.",
    "drug_examples": [
      "Sorafenib"
    ],
    "drug_examples_raw": "Sorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Maculopapular Rash",
    "cut_id": "CUT027",
    "incidence": "Sorafenib (20–30%), Sunitinib (10–20%)",
    "tti": "1-8 weeks",
    "management_prevention": "Management: Use moisturizers and mild cleansers. Grade 1-2: Topical steroids (Class 3-4), Oral antihistamines. Grade 3: Interrupt drug, Short-term systemic steroids.",
    "drug_examples": [
      "Sunitinib (Common)",
      "Sorafenib",
      "Pazopanib",
      "Regorafenib",
      "Cabozantinib",
      "Vandetanib",
      "Lenvatinib",
      "Axitinib"
    ],
    "drug_examples_raw": "Sunitinib (Common), Sorafenib, Pazopanib, Regorafenib, Cabozantinib, Vandetanib, Lenvatinib, Axitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Oral Mucositis / Stomatitis",
    "cut_id": "CUT040",
    "incidence": "Sunitinib(>10%), Sorafenib, Pazopanib(<10%, Rare)",
    "tti": "Not specified",
    "management_prevention": "Prevention: Oral hygiene maintenance. Management: Topical steroid gargle/application. Local anesthetics(Lidoc for pain.",
    "drug_examples": [
      "Sorafenib",
      "Sunitinib",
      "Pazopanib"
    ],
    "drug_examples_raw": "Sorafenib, Sunitinib, Pazopanib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Scrotal erythema and ulceration",
    "cut_id": "CUT006, CUT033",
    "incidence": "Rare, unspecified",
    "tti": "Not specified",
    "management_prevention": "Management: Dose modification or temporary hold. Topical management(prevention of infection, promote wound healing)",
    "drug_examples": [
      "Sunitinib"
    ],
    "drug_examples_raw": "Sunitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Seborrheic dermatitis-like eruption (Facial and scalp erythema/scale)",
    "cut_id": "CUT005",
    "incidence": "Not specified",
    "tti": "1-8 weeks",
    "management_prevention": "Management: Topical antifungals (Ketoconazole), Mild topical steroids.",
    "drug_examples": [
      "Sorafenib"
    ],
    "drug_examples_raw": "Sorafenib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Skin Hypopigmentation / Depigmentation",
    "cut_id": "CUT031",
    "incidence": "Pazopanib (1-10%)",
    "tti": "Early onset (Sunitinib: might be within one week)",
    "management_prevention": "Management: No treatment required. Educate patient that it is reversible upon discontinuation.",
    "drug_examples": [
      "Pazopanib",
      "Sunitinib"
    ],
    "drug_examples_raw": "Pazopanib, Sunitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Subungual splinter hemorrhages",
    "cut_id": "CUT016",
    "incidence": "Rare, unspecified",
    "tti": "Not specified",
    "management_prevention": "Management: No treatment required if painless. Resolves naturally.",
    "drug_examples": [
      "Sorafenib",
      "Sunitinib"
    ],
    "drug_examples_raw": "Sorafenib, Sunitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "Multikinase Inhibitors (MKIs)",
    "phenotype": "Yellow discoloration of skin",
    "cut_id": "CUT038",
    "incidence": ">10%",
    "tti": "Usually within one week",
    "management_prevention": "Management: No treatment required. Due to drug metabolite color. Reversible.",
    "drug_examples": [
      "Sunitinib"
    ],
    "drug_examples_raw": "Sunitinib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "PI3K Inhibitors",
    "phenotype": "Dry skin (Xerosis)",
    "cut_id": "CUT004",
    "incidence": "Common",
    "tti": "Not specified",
    "management_prevention": "Management: Moisturizers, Urea creams. Note: Hyperglycemia (Alpelisib) can exacerbate dry skin.",
    "drug_examples": [
      "Alpelisib",
      "Idelalisib",
      "Copanlisib"
    ],
    "drug_examples_raw": "Alpelisib, Idelalisib, Copanlisib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "PI3K Inhibitors",
    "phenotype": "Maculopapular Rash (Rash maculo-papular)",
    "cut_id": "CUT027",
    "incidence": "35-52% (Grade 3+: ~20%)",
    "tti": "1-2 weeks (or first 1-2 cycles)",
    "management_prevention": "Prevention: Prophylactic non-sedating antihistamines (e.g., Cetirizine 10mg) recommended. Management: Grade 1: Topical steroids, moisturizers. Grade 2: Topical steroids, oral prednisone (0.5-1 mg/kg). Grade 3: Hold drug, systemic steroids (Prednisone 0.5-1 mg/kg) for 10-14 days. Restart at reduced dose upon improvement.",
    "drug_examples": [
      "Alpelisib"
    ],
    "drug_examples_raw": "Alpelisib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "PI3K Inhibitors",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": "Not specified",
    "tti": "Not specified",
    "management_prevention": "Management: Moisturizers, Oral antihistamines.",
    "drug_examples": [
      "Alpelisib"
    ],
    "drug_examples_raw": "Alpelisib"
  },
  {
    "therapy_class": "Targeted therapy",
    "drug_subclass": "PI3K Inhibitors",
    "phenotype": "Stomatitis / mIAS",
    "cut_id": "CUT040",
    "incidence": "Lower frequency than mTOR inhibitors",
    "tti": "Not specified",
    "management_prevention": "Prevention: Alcohol-free Dexamethasone mouthwash (0.5 mg/5 mL) swish and spit 4 times daily. Management: Grade 1: Non-alcoholic mouthwash, salt water. Grade 2: Topical steroids (Triamcinolone), topical anesthetics. Hold drug. Grade 3: Interrupt drug until Grade ≤1, then restart at reduced dose. Avoid alcohol/hydrogen peroxide mouthwashes.",
    "drug_examples": [
      "Alpelisib (Common)",
      "Copanlisib",
      "Idelalisib",
      "Duvelisib",
      "Umbralisib",
      "Inavolisib"
    ],
    "drug_examples_raw": "Alpelisib (Common), Copanlisib, Idelalisib, Duvelisib, Umbralisib, Inavolisib"
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Alopecia",
    "cut_id": "CUT001",
    "incidence": "1-2%",
    "tti": "Usually 3-6 months later",
    "management_prevention": "Management: Wigs (Grade 1), Topical Minoxidil (may help shorten duration), topical steroids (non-scarring).",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Autoimmune Bullous Dermatoses (Bullous pemphigoid)",
    "cut_id": "CUT044",
    "incidence": "~1% (Rare)",
    "tti": "~13-15 weeks (or later)",
    "management_prevention": "Diagnosis: Skin biopsy (DIF), BP180/BP230 antibodies. Management: Mild: Potent topical steroids. Moderate+: Stop ICI, Systemic steroids (0.5-2 mg/kg). Refractory: Rituximab, Omalizumab, Dapsone, Methotrexate.",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Atezolizumab",
      "etc. (Mainly PD-1/PD-L1)"
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Atezolizumab, etc. (Mainly PD-1/PD-L1)"
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Dermatomyositis",
    "cut_id": "CUT052",
    "incidence": "Rare",
    "tti": "Not specified",
    "management_prevention": "Management: High-dose IV Methylprednisolone (1–2 mg/kg/day or pulse therapy), Oral Prednisone (1 mg/kg/day). Refractory: IVIG, Plasmapheresis, or other immunosuppressants (Methotrexate, Azathioprine, Mycophenolate Mofetil)",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "DRESS Syndrome",
    "cut_id": "CUT043",
    "incidence": "Rare",
    "tti": "2-8 weeks",
    "management_prevention": "Management: Similar to SJS/TEN (Systemic steroids, supportive care).",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Lichenoid eruption (Lichenoid dermatitis)",
    "cut_id": "CUT015",
    "incidence": "Not specified (More common in PD-1/PD-L1)",
    "tti": "6-12 weeks",
    "management_prevention": "Management: First-line: Potent topical steroids (Clobetasol). Refractory/Widespread: Oral steroids or NB-UVB phototherapy. Steroid-sparing agents: Acitretin, Methotrexate, Hydroxychloroquine.",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Atezolizumab",
      "etc. (Mainly PD-1/PD-L1)"
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Atezolizumab, etc. (Mainly PD-1/PD-L1)"
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Maculopapular rash (Morbilliform)",
    "cut_id": "CUT027",
    "incidence": "49-68%",
    "tti": "3-6 weeks (Early)",
    "management_prevention": "Prevention: Hypoallergenic moisturizers BID, tepid showers, sun protection. Management: Grade 1 (<10% BSA): Continue ICI. Topical steroids (mid-high potency), oral antihistamines, moisturizers. Grade 2 (10-30% BSA): Consider holding ICI. High potency topical steroids, oral antihistamines. Systemic steroids (Prednisone 0.5-1 mg/kg) if persistent. Grade 3 (>30% BSA): Hold ICI. Systemic steroids (Prednisone 1-2 mg/kg), taper over 4-6 weeks. Grade 4: Permanently discontinue ICI. IV Methylprednisolone 1-2 mg/kg. Admit to burn unit.",
    "drug_examples": [
      "Ipilimumab",
      "Tremelimumab"
    ],
    "drug_examples_raw": "CTLA-4i: Ipilimumab, Tremelimumab"
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Oral Mucositis",
    "cut_id": "CUT040",
    "incidence": "Not specified",
    "tti": "Not specified",
    "management_prevention": "Management: Topical steroid gargle (Dexamethasone), Ointment, Lidocaine solution. Systemic steroids if severe.",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": "13-20% (Higher in CTLA-4)",
    "tti": "Immediate or within weeks",
    "management_prevention": "Management: Grade 1-2: Topical steroids, Menthol, Pramoxine, Oral antihistamines (Cetirizine, Hydroxyzine). Grade 3 (Severe/Refractory): GABA agonists (Gabapentin, Pregabalin), NK-1 receptor antagonists (Aprepitant). Biologics like Dupilumab or Omalizumab reported effective for refractory cases.",
    "drug_examples": [
      "Ipilimumab",
      "Tremelimumab (More common CTLA-4 > PD-1/PD-L1)",
      "Nivolumab",
      "Pembrolizumab",
      "etc."
    ],
    "drug_examples_raw": "Ipilimumab, Tremelimumab (More common CTLA-4 > PD-1/PD-L1); Nivolumab, Pembrolizumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Psoriasis / Psoriasiform",
    "cut_id": "CUT002",
    "incidence": "~12%",
    "tti": "Usually 3-12 weeks",
    "management_prevention": "Management: Topical steroids, Vitamin D analogs. Severe: Acitretin, Methotrexate, Apremilast. Caution with biologics (IL-17/IL-23 inhibitors).",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Scleroderma",
    "cut_id": "CUT051",
    "incidence": "Rare",
    "tti": "Not specified",
    "management_prevention": "Management: Hold ICI, Prednisone 0.5–1 mg/kg/day. DMARDs (Methotrexate, Anti-TNF- α, IL-6 antagonists) may be considered for refractory arthritis, which often co-occurs",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "SJS / TEN (Stevens-Johnson syndrome / Toxic Epidermal Necrolysis)",
    "cut_id": "CUT034",
    "incidence": "Rare",
    "tti": "Months later",
    "management_prevention": "Management: Permanent discontinuation of ICI. ICU admission. High-dose IV steroids (Methylprednisolone 1-2 mg/kg/day). IVIG, Cyclosporine, Infliximab if steroid-refractory.",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Immune Checkpoint Inhibitors (ICI)",
    "drug_subclass": "Immune Checkpoint Inhibitors",
    "phenotype": "Vitiligo-like depigmentation (Vitiligo)",
    "cut_id": "CUT031",
    "incidence": "~25% (in Melanoma patients)",
    "tti": "Months after start",
    "management_prevention": "Management: Usually no treatment required (continue ICI). Educate on sun protection (burn prevention). Topical steroids or calcineurin inhibitors have limited effect. Considered a positive prognostic factor.",
    "drug_examples": [
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "etc."
    ],
    "drug_examples_raw": "Nivolumab, Pembrolizumab, Ipilimumab, etc."
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Acneiform Rash",
    "cut_id": "CUT042",
    "incidence": "Docetaxel: associated",
    "tti": "Not specified",
    "management_prevention": "Management: Not specified.",
    "drug_examples": [
      "Taxanes"
    ],
    "drug_examples_raw": "Taxanes"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Acute Generalized Exanthematous Pustulosis (AGEP)",
    "cut_id": "CUT047",
    "incidence": "Rare",
    "tti": "Not specified",
    "management_prevention": "Management: Not specified.",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel"
    ],
    "drug_examples_raw": "Docetaxel, Paclitaxel"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Alopecia (Anagen effluvium)",
    "cut_id": "CUT001",
    "incidence": "Estimated overall incidence: 65%. High risk: Taxanes (>80%), Anthracyclines (60–100%)",
    "tti": "Usually occurs within 7–10 days. Typically within 2–4 weeks",
    "management_prevention": "Prevention: Scalp cooling (effective for Taxanes/Anthracyclines). Management: Wigs, sun protection. Minoxidil may help hair regrowth speed after treatment. Topical steroids if inflammation exists on biopsy.",
    "drug_examples": [
      "Paclitaxel",
      "Docetaxel Anthracyclines: Doxorubicin Alkylating: Cyclophosphamide",
      "Ifosfamide"
    ],
    "drug_examples_raw": "Taxanes: Paclitaxel, Docetaxel Anthracyclines: Doxorubicin Alkylating: Cyclophosphamide, Ifosfamide"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Dry skin (Xerosis, Scaling)",
    "cut_id": "CUT004",
    "incidence": "Common",
    "tti": "Epidermal barrier damage occurs early in treatment",
    "management_prevention": "Prevention: Emoilients Management: Bland emollients (Moisturizers).",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel Alkylating: Estramustine",
      "Temozolomide"
    ],
    "drug_examples_raw": "Taxanes: Docetaxel, Paclitaxel Alkylating: Estramustine, Temozolomide"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Edema (Peripheral pitting edema)",
    "cut_id": "CUT038",
    "incidence": "20-60%(Docetaxel - common)",
    "tti": "Docetaxel: onset related to cumulative dose (>400 mg/m2 or 4th–5th cycle)",
    "management_prevention": "Management: Premedication with steroids. Diuretics/Compression/Physical therapy. Dose modification/interruption",
    "drug_examples": [
      "Docetaxel"
    ],
    "drug_examples_raw": "Docetaxel"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Erythema (Intertriginous/Flexural eruption)",
    "cut_id": "CUT006",
    "incidence": "Liposomal Doxorubicin: can cause intertrigo-like rash (8% incidence). Docetaxel: can cause inflammatory patches in flexural areas",
    "tti": "Not specified",
    "management_prevention": "Management: Low-potency topical corticosteroids (for mild cases). Topical antifungals/azoles (if fungal infection suspected)",
    "drug_examples": [
      "Taxanes (Intertriginous eruption)",
      "Pegylated Liposomal Doxorubicin (Intertrigo-like rash)"
    ],
    "drug_examples_raw": "Taxanes (Intertriginous eruption), Pegylated Liposomal Doxorubicin (Intertrigo-like rash)"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Erythema multiforme",
    "cut_id": "CUT006",
    "incidence": "Docetaxel, Fludarabine reported",
    "tti": "Not specified",
    "management_prevention": "Management: Stop offending agent. Systemic corticosteroids and IVIG use is controversial",
    "drug_examples": [
      "Methotrexate",
      "Bleomycin"
    ],
    "drug_examples_raw": "Methotrexate, Bleomycin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Folliculitis (Sterile)",
    "cut_id": "CUT042",
    "incidence": "Taxanes: reported (sterile pustular eruption)",
    "tti": "Not specified",
    "management_prevention": "Management: Not specified (Noted as sterile).",
    "drug_examples": [
      "Taxanes"
    ],
    "drug_examples_raw": "Taxanes"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Hand-Foot Syndrome (HFS) (Palmar-Plantar Erythrodysesthesia)",
    "cut_id": "CUT039",
    "incidence": "Capecitabine: 50–60% (All Grades); 10–17% (Severe/G3-4). PLD: 40–50% (All Grades); 20% (Severe). Taxanes (Docetaxel): 5–10%.",
    "tti": "Typically within 1 day to several weeks after starting CTX",
    "management_prevention": "Prevention: Celecoxib (proven in RCT for Capecitabine), Urea 10% cream, Cooling (for Pegylated Liposomal Doxorubicin or Docetaxel). Pyridoxine is not recommended. Management: Cold compress, moisturizers, potent topical steroids, analgesics. Grade 2-3: Dose reduction or interruption.",
    "drug_examples": [
      "Capecitabine (Most common)",
      "Doxorubicin",
      "5-Fluorouracil (5-FU)",
      "Cytarabine",
      "Taxanes (Docetaxel > Paclitaxel)",
      "Methotrexate"
    ],
    "drug_examples_raw": "Capecitabine (Most common), Doxorubicin, 5-Fluorouracil (5-FU), Cytarabine, Taxanes (Docetaxel > Paclitaxel), Methotrexate"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Inflammation of Actinic Keratoses",
    "cut_id": "CUT038",
    "incidence": "Fluorouracil, Docetaxel, Doxorubicin, Cytarabine, Paclitaxel: associated",
    "tti": "Develops in the first week of chemotherapy",
    "management_prevention": "Management: Topical corticosteroids",
    "drug_examples": [
      "5-FU",
      "Docetaxel",
      "Cisplatin"
    ],
    "drug_examples_raw": "5-FU, Docetaxel, Cisplatin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Nail changes (Onycholysis, Onychomadesis, Subungual abscess)",
    "cut_id": "CUT016, CUT018",
    "incidence": "Docetaxel (34.9%), Paclitaxel (43.7%)",
    "tti": "Nail changes are evident after several weeks of treatment. Onycholysis/Abscess: may begin within a few weeks",
    "management_prevention": "Prevention: Frozen gloves/socks (Cooling). Management: Keep nails short, avoid trauma. Soaking in diluted vinegar (1:1 or 1:10) for onycholysis. Saline soaking, Topical steroids/antibiotics for inflammation/infection.",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel"
    ],
    "drug_examples_raw": "Docetaxel, Paclitaxel"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Nail discoloration (Diffuse or banded hyperpigmentation, Melanonychia)",
    "cut_id": "CUT017",
    "incidence": "Cyclophosphamide, Doxorubicin, Hydroxyurea: commonly induce pigmentation",
    "tti": "Melanonychia: develops after several months of therapy",
    "management_prevention": "Management: Camouflage with nail polish",
    "drug_examples": [
      "Cyclophosphamide",
      "Doxorubicin",
      "Hydroxyurea"
    ],
    "drug_examples_raw": "Cyclophosphamide, Doxorubicin, Hydroxyurea"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Oral Mucositis / Stomatitis",
    "cut_id": "CUT040",
    "incidence": "Very common",
    "tti": "few days after administration",
    "management_prevention": "Prevention: Oral cryotherapy (Ice chips) for 5-FU. Management: Dexamethasone mouthwash, supportive care(lidocaine, etc)",
    "drug_examples": [
      "5-FU",
      "Melphalan",
      "Cisplatin (90% with RT)",
      "Docetaxel",
      "Bendamustine",
      "Ifosfamide",
      "Bleomycin",
      "Doxorubicin"
    ],
    "drug_examples_raw": "5-FU, Melphalan, Cisplatin (90% with RT), Docetaxel, Bendamustine, Ifosfamide, Bleomycin, Doxorubicin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Paronychia (Periungual inflammation)",
    "cut_id": "CUT041",
    "incidence": "Commonly reported with Capecitabine/Methotrexate/Doxorubicin/Taxanes",
    "tti": "Develops after several weeks or months of treatment",
    "management_prevention": "Management: Topical steroids, antibiotic ointment. Severe cases: Surgical drainage.",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel"
    ],
    "drug_examples_raw": "Docetaxel, Paclitaxel"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Persistent Alopecia (CIPAL)",
    "cut_id": "CUT001",
    "incidence": "Permanent loss ≥ 6 months post-cessation. Higher risk: Docetaxel (2% incidence reported), Busulfan",
    "tti": "Occurs >6 months after cessation",
    "management_prevention": "Management: Topical Minoxidil (up to 5%): may potentially stimulate regrowth. Surgical (hair transplantation)",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel Alkylating: Busulfan (High dose)"
    ],
    "drug_examples_raw": "Taxanes: Docetaxel, Paclitaxel Alkylating: Busulfan (High dose)"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Photosensitivity (Phototoxicity)",
    "cut_id": "CUT023",
    "incidence": "Fluorouracil, Capecitabine, Dacarbazine, Vinblastine: involved. Paclitaxel, Docetaxel: cause UV recall",
    "tti": "Sunburn-like reactions: within minutes to weeks/months",
    "management_prevention": "Prevention: Strict sun protection (Sunscreen, protective clothing). Management: Cessation of causing agents, Topical/Systemic steroids, NSAIDs, antihistamines.",
    "drug_examples": [
      "Methotrexate (Common)",
      "5-FU",
      "Dacarbazine",
      "Taxanes (Paclitaxel",
      "Docetaxel)"
    ],
    "drug_examples_raw": "Methotrexate (Common), 5-FU, Dacarbazine, Taxanes (Paclitaxel, Docetaxel)"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": ">10%",
    "tti": "Occurs shortly after infusion",
    "management_prevention": "Prevention: moisturization/skin care Management: antihistsamines, topical antipruritics",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel"
    ],
    "drug_examples_raw": "Taxanes: Docetaxel, Paclitaxel"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Radiation Recall Dermatitis",
    "cut_id": "CUT046",
    "incidence": "Doxorubicin, Capecitabine, Gemcitabine, Docetaxel, Paclitaxel: involved",
    "tti": "During, immediately after, or within days of chemo",
    "management_prevention": "Management: Cessation/delay, Topical, systemic corticosteroids.",
    "drug_examples": [
      "Taxanes",
      "Doxorubicin",
      "Gemcitabine",
      "Methotrexate",
      "Cisplatin",
      "Dactinomycin"
    ],
    "drug_examples_raw": "Taxanes, Doxorubicin, Gemcitabine, Methotrexate, Cisplatin, Dactinomycin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Rash maculo-papular (Diffuse macules and papules, Morbilliform eruption)",
    "cut_id": "CUT027",
    "incidence": "Cladribine, Gemcitabine, Fludarabine: reported. Gemcitabine: reported in 19%",
    "tti": "Gemcitabine (Etoposide similar): begins about 1 week after initiation",
    "management_prevention": "Management: Topical steroids or systemic corticosteroids Severe cases: Dose reduction or interruption.",
    "drug_examples": [
      "Docetaxel (Very common)",
      "Paclitaxel Alkylating: Temozolomide",
      "Estramustine"
    ],
    "drug_examples_raw": "Taxanes: Docetaxel (Very common), Paclitaxel Alkylating: Temozolomide, Estramustine"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Skin hyperpigmentation (Flagellate dermatitis, Serpentine supravenous hyperpigmentation)",
    "cut_id": "CUT030",
    "incidence": "Bleomycin (Flagellate dermatitis): up to 30%. Taxanes (Serpentine): reported",
    "tti": "Bleomycin (Flagellate): onset is hours to months after infusion",
    "management_prevention": "Prevention: Strict sun avoidance Management: Flagellate Dermatitis: resolves 3–4 months post-cessation. Topical retinoids (for improved melanin turnover)",
    "drug_examples": [
      "Bleomycin (Flagellate)",
      "5-FU/Taxanes/Vinorelbine (Serpentine supravenous)",
      "Cyclophosphamide (Diffuse/Palms/Soles/Teeth)",
      "Ifosfamide (Flexural)"
    ],
    "drug_examples_raw": "Bleomycin (Flagellate), 5-FU/Taxanes/Vinorelbine (Serpentine supravenous), Cyclophosphamide (Diffuse/Palms/Soles/Teeth), Ifosfamide (Flexural)"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Skin ulceration (Extravasation / Tissue necrosis)",
    "cut_id": "CUT033",
    "incidence": "Anthracyclines (Doxorubicin), Vinca alkaloids (Vincristine), Taxanes (Paclitaxel, Docetaxel): primary vesicants",
    "tti": "Onset is subclinical initially (burning, erythema) followed by necrosis after 2–3 days",
    "management_prevention": "Management: Stop infusion immediately, aspirate drug. Cold pack: Anthracyclines, Taxanes, Alkylating agents. Warm pack: Vinca Alkaloids, Etoposide. Antidotes: Dexrazoxane/DMSO (Anthracyclines), Hyaluronidase (Vinca Alkaloids).",
    "drug_examples": [
      "Doxorubicin Vinca Alkaloids: Vincristine",
      "Vinblastine Mitotic: Taxanes"
    ],
    "drug_examples_raw": "Anthracyclines: Doxorubicin Vinca Alkaloids: Vincristine, Vinblastine Mitotic: Taxanes"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Stiff skin (Scleroderma-like changes, Cutaneous sclerosis/fibrosis)",
    "cut_id": "CUT032",
    "incidence": "Paclitaxel/Docetaxel: cause cutaneous sclerosis. Bleomycin: cause localized sclerosis.",
    "tti": "Progressive over several months",
    "management_prevention": "Management: Resolves upon drug discontinuation. Prednisone +(Methotexate)",
    "drug_examples": [
      "Docetaxel",
      "Paclitaxel",
      "Bleomycin"
    ],
    "drug_examples_raw": "Docetaxel, Paclitaxel, Bleomycin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "Urticaria (Hypersensitivity reaction)",
    "cut_id": "CUT037",
    "incidence": "Platinum drugs, Taxanes, Cyclophosphamide: common offenders",
    "tti": "Minutes to days after infusion",
    "management_prevention": "Prevention: Pretreatment with steroids/antihistamines. Desensitization protocols Management: Antihistamines and corticosteroids",
    "drug_examples": [
      "Cisplatin",
      "Carboplatin"
    ],
    "drug_examples_raw": "Cisplatin, Carboplatin"
  },
  {
    "therapy_class": "Cytotoxic chemotherapy",
    "drug_subclass": "Cytotoxic Chemotherapy",
    "phenotype": "UV Recall Reaction (Inflammation on previous solar erythema)",
    "cut_id": "CUT023",
    "incidence": "Paclitaxel, Docetaxel: causative agents. Methotrexate also implicated",
    "tti": "Days or weeks after chemo (on old burn site)",
    "management_prevention": "Prevention: Sun avoidance Management: Removal of offending agent (chemotherapy). Topical/Systemic Corticosteroids (for symptomatic relief)",
    "drug_examples": [
      "Methotrexate",
      "Gemcitabine",
      "Taxanes"
    ],
    "drug_examples_raw": "Methotrexate, Gemcitabine, Taxanes"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Acneiform Rash",
    "cut_id": "CUT042",
    "incidence": "Not specified (Common in ADC class)",
    "tti": "Early treatment (Within several weeks)",
    "management_prevention": "Management: Similar to general rash management.",
    "drug_examples": [
      "Tisotumab vedotin (TV)",
      "General ADCs"
    ],
    "drug_examples_raw": "Tisotumab vedotin (TV), General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Alopecia",
    "cut_id": "CUT001",
    "incidence": "Sacituzumab govitecan (SG): 46~50% (All Grades), Trastuzumab deruxtecan (T-DXd): 37% (All Grades), Datopotamab deruxtecan (Dato-DXd): 65% (All Grades)",
    "tti": "Not specified (Generally, several months after initiation)",
    "management_prevention": "Management: Wigs, supportive care. Scalp cooling may be effective for T-DXd (evidence accumulating).",
    "drug_examples": [
      "Sacituzumab govitecan (SG)",
      "Trastuzumab deruxtecan (T-DXd)",
      "Datopotamab deruxtecan (Dato-DXd)"
    ],
    "drug_examples_raw": "Sacituzumab govitecan (SG), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Dermatosis bullous (Bullous lesions)",
    "cut_id": "CUT003",
    "incidence": "Not specified (Part of severe ADC toxicity)",
    "tti": "Not specified (Within the first cycle of treatment for EV)",
    "management_prevention": "Management: Immediate interruption (Hold). If severe, permanently discontinue. Systemic steroids. Rule out SJS/TEN.",
    "drug_examples": [
      "Enfortumab vedotin (EV)"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "DRESS Syndrome",
    "cut_id": "CUT043",
    "incidence": "Not specified (Rare, Case Reports with Brentuximab vedotin, Enfortumab vedotin, etc.)",
    "tti": "2–8 weeks",
    "management_prevention": "Management: Immediate discontinuation. Systemic steroids.",
    "drug_examples": [
      "Brentuximab vedotin (BV)"
    ],
    "drug_examples_raw": "Brentuximab vedotin (BV)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Dry skin (Xerosis)",
    "cut_id": "CUT004",
    "incidence": "Not specified (Common)",
    "tti": "Not specified",
    "management_prevention": "Management: Moisturizers.",
    "drug_examples": [
      "General ADCs"
    ],
    "drug_examples_raw": "General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Erythema (SDRIFE-like rash in intertriginous areas)",
    "cut_id": "CUT006",
    "incidence": "Not specified (Characteristic of EV)",
    "tti": "Within days to several weeks after initiation (EV standard)",
    "management_prevention": "Prevention: Zinc-containing moisturizers on intertriginous areas. Management: Topical steroids, moisturizers.",
    "drug_examples": [
      "Enfortumab vedotin (EV)"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Erythroderma (Exfoliative dermatitis)",
    "cut_id": "CUT007",
    "incidence": "Not specified (Part of EV Grade ≥3 toxicity)",
    "tti": "Within the first cycle of treatment (EV standard)",
    "management_prevention": "Management: Treat as severe skin reaction (Grade 3). Stop drug and administer systemic steroids.",
    "drug_examples": [
      "Enfortumab vedotin (EV)"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Hand-Foot Syndrome (HFS) (PPE)",
    "cut_id": "CUT039",
    "incidence": "Not specified (Reported with Enfortumab vedotin)",
    "tti": "Within days to several weeks after initiation (EV standard)",
    "management_prevention": "Management: Standard HFS management (Moisturizers, Urea).",
    "drug_examples": [
      "General ADCs"
    ],
    "drug_examples_raw": "General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Lichenoid dermatitis (Lichenoid rash)",
    "cut_id": "CUT015",
    "incidence": "Not specified (Common in ADC class)",
    "tti": "Early treatment (6–12 weeks)",
    "management_prevention": "Management: Grade 1-2: Topical corticosteroids (TCS) (topical intervention indicated),,; Severe (Grade ≥ 3): Hold ADC/ICI therapy, initiate high-dose systemic corticosteroids",
    "drug_examples": [
      "General ADCs"
    ],
    "drug_examples_raw": "General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Maculopapular Rash (Rash, Maculopapular rash)",
    "cut_id": "CUT027",
    "incidence": "EV: 56% (All skin reactions), 24% (Maculopapular); General: Common",
    "tti": "EV: Within 1 month (1st cycle); General: Within weeks",
    "management_prevention": "Prevention: EV: Apply Zinc-containing moisturizers to intertriginous areas. Sunscreen. Management: Grade 1: Moisturizers, topical steroids, oral antihistamines. Grade 2: Potent topical steroids. Hold drug until improved to Grade ≤1. Grade 3: Permanently discontinue EV (for severe/bullous). Systemic steroids (Prednisone 0.5-1 mg/kg).",
    "drug_examples": [
      "Enfortumab vedotin (EV)",
      "Sacituzumab govitecan (SG)",
      "Brentuximab vedotin (BV)",
      "Loncastuximab tesirine (LT)",
      "General ADCs"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV), Sacituzumab govitecan (SG), Brentuximab vedotin (BV), Loncastuximab tesirine (LT), General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Oral Mucositis / Stomatitis",
    "cut_id": "CUT040",
    "incidence": "Dato-DXd: 69%, T-DXd: 20%, SG: 17%",
    "tti": "Not specified (Generally, within 8 weeks after initiation)",
    "management_prevention": "Prevention: Dexamethasone mouthwash gargle. Management: Soft toothbrush, avoid irritants. Topical anesthetics/coating agents.",
    "drug_examples": [
      "Sacituzumab govitecan (SG)",
      "Trastuzumab deruxtecan (T-DXd)",
      "Datopotamab deruxtecan (Dato-DXd)"
    ],
    "drug_examples_raw": "Sacituzumab govitecan (SG), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Photosensitivity (Phototoxic rash)",
    "cut_id": "CUT023",
    "incidence": "Not specified (Reported with Loncastuximab tesirine)",
    "tti": "Not specified",
    "management_prevention": "Prevention: Minimize sun exposure. Wear sun-protective clothing (essential due to PBD payload). Sunscreen. Management: Steroids have limited effect.",
    "drug_examples": [
      "Loncastuximab tesirine (LT)"
    ],
    "drug_examples_raw": "Loncastuximab tesirine (LT)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Pruritus",
    "cut_id": "CUT024",
    "incidence": "Enfortumab vedotin (EV): 33% (All Grades), T-DXd: 8% (All Grades)",
    "tti": "Early treatment (Within several weeks)",
    "management_prevention": "Management: Oral antihistamines, moisturizers.",
    "drug_examples": [
      "General ADCs (e.g.",
      "Tisotumab vedotin)"
    ],
    "drug_examples_raw": "General ADCs (e.g., Tisotumab vedotin)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Skin hyperpigmentation",
    "cut_id": "CUT030",
    "incidence": "T-DXd: 6% (All Grades)",
    "tti": "Not specified",
    "management_prevention": "Prevention: Strict sun avoidance with broad spectrum UV protection. Management: Camouflage discoloration, topical retinoids, hydroquinone",
    "drug_examples": [
      "General ADCs"
    ],
    "drug_examples_raw": "General ADCs"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Stevens-Johnson syndrome (SJS)",
    "cut_id": "CUT034",
    "incidence": "Not specified (Rare, reported as SCAR in ADCs)",
    "tti": "1–8 weeks (Standard for targeted therapy SCARs)",
    "management_prevention": "Management: Permanently discontinue drug immediately. Hospitalization, high-dose systemic steroids (Methylprednisolone), supportive care.",
    "drug_examples": [
      "Enfortumab vedotin (EV)",
      "Polatuzumab vedotin (with Rituximab)"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV), Polatuzumab vedotin (with Rituximab)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Telangiectasia (Spider angioma-like, Diffuse reticulated)",
    "cut_id": "CUT035",
    "incidence": "Not specified (Characteristic of T-DM1)",
    "tti": "Not specified",
    "management_prevention": "Management: T-DM1: Laser therapy or Electrocautery for persistent lesions (cosmetic/psychological benefit).",
    "drug_examples": [
      "Loncastuximab tesirine (LT)",
      "Trastuzumab emtansine (T-DM1)"
    ],
    "drug_examples_raw": "Loncastuximab tesirine (LT), Trastuzumab emtansine (T-DM1)"
  },
  {
    "therapy_class": "Antibody Drug Conjugates (ADC)",
    "drug_subclass": "Antibody-Drug Conjugates (ADCs)",
    "phenotype": "Toxic Epidermal Necrolysis (TEN)",
    "cut_id": "CUT034",
    "incidence": "Not specified (Rare, reported as SCAR in ADCs)",
    "tti": "1–8 weeks (Standard for targeted therapy SCARs)",
    "management_prevention": "Management: Same as SJS. Permanently discontinue.",
    "drug_examples": [
      "Enfortumab vedotin (EV)",
      "Polatuzumab vedotin"
    ],
    "drug_examples_raw": "Enfortumab vedotin (EV), Polatuzumab vedotin"
  }
]